Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Lexicon’s biopharmaceutical operations, financial condition, capital-raising activities and risks associated with its pipeline in heart failure, hypertrophic cardiomyopathy, neuropathic pain, obesity, diabetes and related indications.
Investors can review current reports on Form 8-K, where Lexicon discloses material events such as quarterly financial results, at-the-market equity offering arrangements, Nasdaq listing status updates and key business developments. For example, recent 8-K filings describe an Open Market Sale Agreement with Jefferies LLC, legal opinions related to potential share sales, and communications regarding compliance with Nasdaq’s minimum bid price requirement and transfer to The Nasdaq Capital Market.
In addition to 8-Ks, users can locate Lexicon’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR), which typically contain audited financial statements, management’s discussion and analysis, detailed descriptions of products such as sotagliflozin (INPEFA®), pilavapadin (LX9211) and LX9851, as well as information on licensing agreements with partners like Viatris and Novo Nordisk. Proxy materials and other filings may address executive compensation, governance and shareholder matters.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy reports, helping users quickly understand major changes in revenue sources, R&D priorities, collaboration structures, risk factors and capital structure. Real-time updates from EDGAR ensure that new Lexicon filings, including any Form 4 insider transaction reports, become accessible promptly, while AI-generated overviews make complex regulatory language more approachable for both individual and institutional investors.
Lexicon Pharmaceuticals’ Chief Executive Officer and director Michael Exton reported equity awards dated February 12, 2026. He received 862,440 restricted stock units, each representing a right to one share of common stock. These restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year.
He was also granted a stock option for 1,293,670 shares of common stock at an exercise price of $1.37 per share. The option vests 25% on the first anniversary of the grant date and then 1/48th of the shares each month of continued service thereafter.
Avicenna Life Sci Master Fund LP and its general partner Avicenna Life Sci Master GP LLC reported their initial insider status in Lexicon Pharmaceuticals. As of February 2, 2026, the fund indirectly beneficially owned 1,538,462 shares of Lexicon common stock.
The filing identifies both Avicenna entities as a director and 10% owner group, with the common stock directly held by Avicenna Life Sci Master Fund LP. The reporting persons disclaim beneficial ownership of securities held by the other related reporting persons except to the extent of their pecuniary interest.
Lexicon Pharmaceuticals disclosed significant share purchases by investment entities tied to Invus and Artal as part of a financing that closed on February 2, 2026. Artal Participations S.a r.l. agreed to buy 22,400,000 common shares at
Artal Participations S.a r.l. also agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock at
Lexicon Pharmaceuticals’ major shareholders have updated their ownership and financing arrangements following a new capital raise. An investor group led by Artal and Invus now collectively reports beneficial ownership of 205,952,227 Lexicon common shares, representing approximately 48.2% of the 427,084,567 shares outstanding as of the recent financing.
Artal Participations agreed to buy 22,400,000 common shares for $29,120,000 and 367,145.12 shares of Series B convertible preferred stock for $23,864,432.80 in private placements. Invus Public Equities purchased 3,846,154 common shares for $5,000,000.20, and Avicenna Life Sci Master Fund bought 1,538,462 common shares for $2,000,000.60 as part of a 32,000,000‑share underwritten public offering with a 4,800,000‑share option. The new preferred stock will automatically convert into common shares at a 50‑to‑1 ratio once shareholders approve an increase in authorized common shares and related charter steps are completed, subject to antitrust clearance where applicable.
Lexicon Pharmaceuticals has arranged a large equity financing through a public stock sale and related private placements involving its longtime investor Invus. The company agreed to sell 32,000,000 common shares at
Concurrently, Invus affiliates are purchasing 22,400,000 common shares at the same price for a total of
Lexicon Pharmaceuticals is offering 32,000,000 shares of common stock at $1.30 per share in a primary underwritten sale. Underwriters have a 30‑day option to buy up to 4,800,000 additional shares.
Affiliates of Invus, L.P., the largest stockholder, will buy 22,400,000 shares in a concurrent private placement at the same price, and are also purchasing two tranches of non‑voting convertible preferred stock at $65.00 per share that will convert into common stock on a 50‑to‑1 basis after shareholder approval to increase authorized shares and other conditions are met.
Lexicon expects net proceeds of approximately $79.9 million from the offering and the common stock private placement, or $91.9 million if all options are exercised, excluding additional net proceeds from the extra preferred shares. Funds will support continued research and development of its drug candidates, working capital and general corporate purposes. The company reported unaudited year‑end 2025 cash, investments and restricted cash of $125.2 million and a $10 million milestone from Novo Nordisk, with potential for up to an additional $20 million in 2026.
Lexicon Pharmaceuticals updated investors on its cash position, fundraising plans and late-stage pipeline. The company ended 2025 with unaudited cash, investments and restricted cash of $125.2 million, which it believes is sufficient to support planned operations into 2027, subject to final audit.
Lexicon achieved a $10 million milestone payment in January under its Novo Nordisk licensing agreement and may earn up to an additional $20 million in milestones in 2026. The company launched an underwritten public offering of common stock and plans a concurrent private placement to an affiliate of Invus, L.P., its largest stockholder.
The SONATA pivotal Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy is targeting 500 patients, with enrollment completion anticipated in mid-2026 and topline results expected in the first quarter of 2027. The FDA raised no objections to advancing pilavapadin into Phase 3 for diabetic peripheral neuropathic pain, and pooled Phase 2 data showed a two-point average daily pain score reduction at 12 weeks with the 10 mg dose. FDA feedback also indicated that the investigator‑initiated STENO1 study of sotagliflozin may provide sufficient safety data to support a potential resubmission of the ZYNQUISTA NDA in type 1 diabetes in 2026.
Lexicon Pharmaceuticals plans an underwritten public offering of common stock, together with a concurrent private placement to an affiliate of its largest shareholder, Invus, L.P., at the same price as the public deal. The Invus affiliate may instead receive convertible preferred shares if authorized common shares are insufficient, with those preferred shares expected to convert into common stock after shareholder approval of additional authorized shares.
Lexicon expects to use net proceeds from the offering and private placement to fund research and development of its drug candidates, including sotagliflozin and pilavapadin, and for working capital and general corporate purposes. The company recently reported unaudited year-end 2025 cash, investments and restricted cash of $125.2 million and a $10 million milestone from its Novo Nordisk licensing agreement, with the potential for up to $20 million in additional milestones in 2026, which it believes can support planned operations into 2027. As of January 26, 2026, Lexicon had 363,466,277 common shares outstanding, and Invus and its affiliates held approximately 49.7%, giving them significant influence over governance and capital decisions.
Lexicon Pharmaceuticals (LXRX) filed a prospectus supplement tied to its Open Market Sale Agreement with Jefferies, covering potential at‑the‑market sales of common stock with an aggregate sales price of up to $75,000,000 under its effective Form S‑3 shelf. The supplement relates to the shelf registration filed on August 2, 2024 and declared effective on August 15, 2024.
The company also corrected an inadvertent statement in the supplement that suggested Ernst & Young LLP audited the effectiveness of internal control over financial reporting as of December 31, 2024. As a smaller reporting company and non‑accelerated filer, Lexicon is exempt from that requirement, and EY did not perform such an audit. The notice does not constitute an offer or solicitation in jurisdictions where it would be unlawful.
Lexicon Pharmaceuticals launched an at-the-market offering of up to $75,000,000 of common stock through Jefferies as sales agent. No sales have been made to date. Jefferies will receive a 3.0% commission on gross proceeds, and net proceeds will be used to fund research and development and for working capital and general corporate purposes.
An affiliate of Invus, L.P., the company’s largest stockholder, may concurrently purchase shares to maintain its proportionate ownership in connection with sales under the program, but only after yearly issuances under the ATM exceed two percent of shares outstanding as of the prior December 31. Any such purchases would occur in a concurrent private placement at the same price as the public sales.
The common stock trades on Nasdaq as “LXRX.” The last reported sale price was $1.38 per share on November 5, 2025. Shares outstanding were 363,398,860 as of November 5, 2025; this is a baseline figure, not the amount being offered.